|
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results. |
| |
|
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME |
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME |
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics |
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate |
Travel, Accommodations, Expenses - Epizyme |
Other Relationship - Desmoid Tumor Research Foundation |
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine |
| |
|
Consulting or Advisory Role - Adaptimmune; Athenex; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Immunicum; Karma Oncology; Lilly; Merck Serono; Morphotek; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma; UpToDate |
Research Funding - GlaxoSmithKline (Inst) |
Travel, Accommodations, Expenses - PharmaMar |
| |
|
Consulting or Advisory Role - Deciphera; Epizyme; Jazz Pharmaceuticals |
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Cogent Biosciences (Inst); Cornerstone Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Janssen (Inst); Mundipharma (Inst); Pfizer (Inst); Plexxikon (Inst); PTC Therapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Wolters Kluwer |
Expert Testimony - Meyers Law (Inst) |
| |
|
Consulting or Advisory Role - AADi; Coherus Biosciences; Regeneron |
Speakers' Bureau - Bayer; Deciphera |
Research Funding - Exelixis (Inst) |
| |
|
Leadership - Certis Oncology Solutions |
Stock and Other Ownership Interests - AntiCancer; Certis Oncology Solutions |
Honoraria - Galvanize Therapeutics |
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Lilly |
Speakers' Bureau - AADi; Ayala Pharmaceuticals (Inst); Daiichi Sankyo; Deciphera; Eisai; Lilly; MJH Life Sciences; Novartis; RAIN Therapeutics (Inst); Scripps Health; TRACON Pharma (Inst) |
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); deciphera (Inst); Lilly (Inst); Nanocarrier (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; Eisai; Galvanize Therapeutics; Lilly; Novartis |
Other Relationship - Certis Oncology Solutions |
| |
|
|
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology |
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics |
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis |
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma |
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker |
Expert Testimony - Health Advances |
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly |
| |
|
Stock and Other Ownership Interests - Moleculin Biotech |
Consulting or Advisory Role - Eisai |
Research Funding - Ayala Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); MSD (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis |
| |
|
Consulting or Advisory Role - Adaptimmune; Bayer; Daiichi Sankyo; Epizyme |
Research Funding - Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst) |
| |
|
Consulting or Advisory Role - Bayer (Inst) |
| |
|
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I); Medtronic (I) |
Honoraria - Peerview; touchIME |
Consulting or Advisory Role - Epizyme |
Research Funding - Ayala Pharmaceuticals (Inst); Bayer; Epizyme; SpringWorks Therapeutics (Inst); SpringWorks Therapeutics (Inst) |
Travel, Accommodations, Expenses - SpringWorks Therapeutics; SpringWorks Therapeutics |
| |
|
Employment - Abbott Laboratories; Abbvie; Ayala Pharmaceuticals; Global Coalition for Adaptive Research |
Leadership - Biosight; PhotonPharma |
Stock and Other Ownership Interests - Abbott Laboratories; AbbVie; Ayala Pharmaceuticals |
Consulting or Advisory Role - Molecular Templates |
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Global Coalition for Adaptive Research; Global Coalition for Adaptive Research |
| |
|
Employment - Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Ayala Pharmaceuticals |
Travel, Accommodations, Expenses - Ayala Pharmaceuticals |
| |
|
Employment - Advaxis; Ayala Pharmaceuticals |
Leadership - Advaxis; Ayala Pharmaceuticals |
Stock and Other Ownership Interests - Advaxis; Ayala Pharmaceuticals |
Honoraria - Advaxis; Ayala Pharmaceuticals (I) |
| |
|
No Relationships to Disclose |